Anaplastic lymphoma kinase (ALK) (ALK)-gene rearrangements ALK+ are oncogenic drivers found in 3–5% of patients with non-small-cell lung cancers (NSCLCs) [1]. This evidence concerns the gene ALK and non-small cell lung carcinoma.